let's recode what's possible
Derek Adams, Ph.D.
Chief Technology & Manufacturing Officer
Derek Adams, Ph.D., has served as our chief technology and manufacturing officer since March 2017. Prior to joining bluebird, Derek was the senior vice president of CMC at Evelo Biosciences. At Evelo, Derek established the initial process development function and supply chain for clinical studies and drove strategy for product development. Prior to his time at Evelo, he served as vice president of technical and Strategic Product Development at Alexion Pharmaceuticals, where his responsibilities included developing and supporting all manufacturing processes globally as well as global clinical supply chain. His Alexion career also included roles as Plant Manager for Alexion’s Rhode Island Manufacturing facility and head of upstream process development. Derek began his career in process technical support for live virus vaccine production at Merck & Co, Inc. Derek holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering with High Distinction from Worcester Polytechnic Institute (WPI).
Chief Financial Officer
Jason F. Cole, Esq.
Chief Operating & Legal Officer
VP, Portfolio & Program Management
David Davidson, M.D.
Chief Medical Officer
Chief Commercial Officer
Gary Fortin, Ph.D.
Vice President & Franchise Head for Severe Genetic Diseases
Philip D. Gregory, D. Phil.
Chief Scientific Officer
Head of Europe
Chief of Wings
Joanne Smith-Farrell, Ph.D.
Chief Business Officer
Chief People Officer
Board of Directors
Daniel S. Lynch
Chairman - Independent
John O. Agwunobi, M.D.
Herbalife Nutrition Institute
Wendy L. Dixon, Ph.D.
Formerly of Bristol-Myers Squibb Company
Douglas A. Melton, Ph.D.
David P. Schenkein, M.D.
Chairman - Google Ventures
William R. Sellers, M.D.
Core Institute Member, Broad Institute of MIT and Harvard
William R. Sellers, M.D. has served as a member of our board since September 2019. Dr. Sellers currently leads a research group focused on translating genomic discoveries into new therapeutics as a Core Institute Member at the Broad Institute of MIT and Harvard, and as a Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for Biomedical Research overseeing scientists, clinicians and clinical staff on sites in Cambridge, East Hanover, Basel and Shanghai from 2005-2016. During his tenure he conceptualized and directed a collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia and large-scale efforts to functionally characterize the cancer genome. Along with Dr. Carl June, he co-chaired the CART research collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.
Dr. Sellers was previously an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Together with Matthew Meyerson, he initiated and developed large-scale efforts to re-sequence genes in diverse cancer types, which led to the development of the widely used GISTIC algorithm, the discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. In addition, his work advanced the understanding of the molecular mechanisms of growth regulation of the PTEN tumor suppressor gene.
Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Sellers is a former member of the National Cancer Advisory Board.
Formerly of Change Healthcare Holdings, Inc.
Formerly of Johnson & Johnson
Denice Torres has served as a member of our board of directors since August 2020. She has 25 years of management experience in pharmaceuticals, medical devices, and consumer healthcare.
From 2005-2017, Denice served in senior leadership roles at Johnson & Johnson, including Chief Strategy and Transformation Officer for the global medical device business. Denice is credited for leading one of the most significant transformations in J&J history. Following a series of recalls and the initiation of a consent decree, Denice assumed the role of President, McNeil Consumer Healthcare. From 2011-2015, she led the recovery of OTC brands, including the iconic Tylenol portfolio, by transforming the business operations, manufacturing and quality systems, commercialization approach, and creating high levels of employee engagement across all functions of the business. As a result, Healthcare Businesswoman Association (HBA) named Denice Woman of the Year in 2015. At J&J, Denice also served as President of Janssen Pharmaceuticals (CNS) where she drove turnaround growth by evolving operations, commercialization, patient focus, and building a high performing culture.
Before joining J&J, Denice had a highly successful, 14-year career at Lilly where she was the executive director of global neuroscience and director of U.S. women’s health. She is founder of The Mentoring Place, a volunteer platform that focuses on helping accelerate the careers of women.
Denice received a Bachelor of Science in Psychology from Ball State University, Doctor of Jurisprudence from Indiana University, and Master’s in Business Administration from the University of Michigan. She is a member of the Michigan Bar Association.
You are now leaving www.bluebirdbio.com
Links to sites outside of this website are provided as a resource to the viewer. bluebird bio accepts no responsibility for the content of linked sites.